Infectra was originally approved by Health Canada in January 2014 for treatment of patients with ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and rheumatoid arthritis [1]. Now the approval has been extended to cover three extra indications: Crohn’s disease (CD), fistulising Crohn’s disease and ulcerative colitis (UC). Approval for CD and UC was originally not granted due to ‘differences between Inflectra and Remsima and their respective reference products’.

Biosimilars are called subsequent entry biologics (SEBs) in Canada. Inflectra is an SEB to the reference product Remicade (infliximab), and was the first monoclonal antibody SEB to be approved through the Health Canada SEB regulatory pathway.

The addition of CD, fistulising CD and UC to the approved indications was granted on the basis of similarity between Inflectra and the reference product Remicade in product quality, mechanism of action, disease pathophysiology, safety profile, dosage regimen and on clinical experience with the reference product.

Gerry Stefanatos, General Manager, Global Established Pharma Business, Pfizer Canada said that ‘The Health Canada approval of these three additional indications for Inflectra is an important development for patients’.

Related article
Subsequent entry biologics approved in Canada

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Infliximab SEB launched in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jun 24]. Available from: www.gabionline.net/Biosimilars/News/Infliximab-SEB-launched-in-Canada 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.